FDA Approves Nasacort AQ For Children
October 13th, 2008
The U.S. Food and Drug Administration (FDA) has approved Sanofi-aventis’ Nasacort AQ® Nasal Spray (triamcinolone acetonide) for children two to five years of age for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis (Medical News Today).
Related posts:
- New Dx and Tx Guidelines for Allergy
- FDA Approves New Chorea Treatment
- New Treatment Options for Allergy Sufferers
- FDA Approves Fluarix for Pediatric Use
- FDA: H1N1 Vaccine OK for Ages 6 Months and Up